Toll Free: 1-888-928-9744

Genomic Health, Inc. (GHDX) - Product Pipeline Analysis, 2016 Update

Published: Mar 22, 2016 | Pages: 44 | Publisher: GlobalData | Industry: Medical Devices | Report Format: Electronic (PDF)

Summary

Genomic Health, Inc. (Genomic Health) is a provider of genomic-based clinical laboratory services for the treatment of cancer. The company's commercial product portfolio comprises Onco type DX breast cancer test, Onco type DX colon cancer test, and Onco type DX prostate cancer test. It perform extensive research and development activities to optimize the treatment of urologic cancers including prostate, bladder, and kidney cancers, and additional treatment decisions in breast and colon cancers. Genomic Health develops these products using its Onco type DX platform, a technology which uses RT-PCR approach to improve cancer treatment decisions. The company has operations in the US, Europe, and Asia through its subsidiaries and offices. Genomic Health is headquartered in Redwood City, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company's portfolio of pipeline products. The report provides key information about the company, its major products and brands.  

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Genomic Health, Inc.
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors' pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
 Table of Contents 
Table of Contents 2
List of Tables  4
List of Figures  5
Genomic Health, Inc. Company Snapshot  6
Genomic Health, Inc. Company Overview  6
Genomic Health, Inc. Pipeline Products and Clinical Trials Overview  7
Genomic Health, Inc. - Pipeline Analysis Overview  9
Business Description  9
Key Facts  10
Genomic Health, Inc. - Major Products and Services  11
Genomic Health, Inc. Pipeline Products by Development Stage  12
Genomic Health, Inc. Pipeline Products Overview  14
Anthracycline Chemotherapy Benefit Test  14
Anthracycline Chemotherapy Benefit Test Product Overview  14
Liquid Biopsy - Based Breast Cancer Test  15
Liquid Biopsy - Based Breast Cancer Test Product Overview  15
Liquid Biopsy-Based Bladder Cancer Test  16
Liquid Biopsy-Based Bladder Cancer Test Product Overview  16
Negative Biopsy Test - Prostate Cancer  17
Negative Biopsy Test - Prostate Cancer Product Overview  17
Next Generation Oncotype DX - Prostate Cancer Assay  18
Next Generation Oncotype DX - Prostate Cancer Assay Product Overview  18
Oncotype Dx - Kidney Cancer  19
Oncotype Dx - Kidney Cancer Product Overview  19
Oncotype Dx Colon Cancer Assay -  Oxaliplatin  20
Oncotype Dx Colon Cancer Assay -  Oxaliplatin Product Overview  20
Oncotype SEQ - Liquid Mutation Panel  21
Oncotype SEQ - Liquid Mutation Panel Product Overview  21
Oncotype SEQ - Tissue Mutation Panel  22
Oncotype SEQ - Tissue Mutation Panel Product Overview  22
Oncotype TRACK  23
Oncotype TRACK Product Overview  23
Prognostic Test - Melanoma  24
Prognostic Test - Melanoma Product Overview  24
Prognostic Test - Non Small Cell Lung Cancer  25
Prognostic Test - Non Small Cell Lung Cancer Product Overview  25
Prognostic Test - Non-Metastatic Renal Cell Carcinoma  26
Prognostic Test - Non-Metastatic Renal Cell Carcinoma Product Overview  26
Genomic Health, Inc. - Key Competitors  27
Genomic Health, Inc. - Key Employees  28
Genomic Health, Inc. - Key Employee Biographies  29
Genomic Health, Inc. - Locations And Subsidiaries  31
Head Office  31
Other Locations & Subsidiaries  31
Recent Developments  32
Genomic Health, Inc., Recent Developments  32
Mar 11, 2016: Genomic Health Announces Five-year Outcomes from International 'PlanB' Study Demonstrating the Clinical Utility of Oncotype DX in Node-positive and High-risk Node-negative Breast Cancer  32
Mar 09, 2016: German National Cancer Guidelines Distinguish Oncotype DX as First and Only Multi-gene Breast Cancer Test with 1A Level of Evidence  33
Mar 01, 2016: Journal of Clinical Oncology Publishes Prospective Outcomes Results from Large International Trial Using Oncotype DX  33
Feb 10, 2016: Genomic Health Announces 2016 Financial Outlook and Provides 2015 Fourth Quarter and Year-End Financial Results  34
Jan 11, 2016: Genomic Health Announces Plans to Launch Liquid Biopsy Mutation Panel in 2016  36
Jan 08, 2016: Genomic Health Announces Preliminary 2015 Revenue and Confirms 2016 Growth Expectations  36
Dec 15, 2015: New "Big Data" Brings Total Number of Breast Cancer Patients Studied to 50,000, Demonstrating Oncotype DX Accurately Predicts Clinical Outcomes  37
Nov 30, 2015: med fusion Expands Molecular Diagnostic Test Menu  38
Nov 16, 2015: Genomic Health Announces Presentation of Eight Oncotype DX Studies at the 2015 CTRC-AACR San Antonio Breast Cancer Symposium  39
Nov 16, 2015: Genomic Health Announces Presentation of Eight Oncotype DX Studies at the 2015 CTRC-AACR San Antonio Breast Cancer Symposium  41
Appendix  44
Methodology  44
About GlobalData  44
Contact Us  44
Disclaimer  44
List of Tables
Genomic Health, Inc. Pipeline Products and Clinical Trials Overview  7
Genomic Health, Inc. Pipeline Products by Equipment Type  7
Genomic Health, Inc. Pipeline Products by Indication  8
Genomic Health, Inc., Key Facts  10
Genomic Health, Inc., Major Products and Services  11
Genomic Health, Inc. Number of Pipeline Products by Development Stage  12
Genomic Health, Inc. Pipeline Products Summary by Development Stage  13
Anthracycline Chemotherapy Benefit Test - Product Status  14
Anthracycline Chemotherapy Benefit Test - Product Description  14
Liquid Biopsy - Based Breast Cancer Test - Product Status  15
Liquid Biopsy - Based Breast Cancer Test - Product Description  15
Liquid Biopsy-Based Bladder Cancer Test - Product Status  16
Liquid Biopsy-Based Bladder Cancer Test - Product Description  16
Negative Biopsy Test - Prostate Cancer - Product Status  17
Negative Biopsy Test - Prostate Cancer - Product Description  17
Next Generation Oncotype DX - Prostate Cancer Assay - Product Status  18
Next Generation Oncotype DX - Prostate Cancer Assay - Product Description  18
Oncotype Dx - Kidney Cancer - Product Status  19
Oncotype Dx - Kidney Cancer - Product Description  19
Oncotype Dx Colon Cancer Assay -  Oxaliplatin - Product Status  20
Oncotype Dx Colon Cancer Assay -  Oxaliplatin - Product Description  20
Oncotype SEQ - Liquid Mutation Panel - Product Status  21
Oncotype SEQ - Liquid Mutation Panel - Product Description  21
Oncotype SEQ - Tissue Mutation Panel - Product Status  22
Oncotype SEQ - Tissue Mutation Panel - Product Description  22
Oncotype TRACK - Product Status  23
Oncotype TRACK - Product Description  23
Prognostic Test - Melanoma - Product Status  24
Prognostic Test - Melanoma - Product Description  24
Prognostic Test - Non Small Cell Lung Cancer - Product Status  25
Prognostic Test - Non Small Cell Lung Cancer - Product Description  25
Prognostic Test - Non-Metastatic Renal Cell Carcinoma - Product Status  26
Prognostic Test - Non-Metastatic Renal Cell Carcinoma - Product Description  26
Genomic Health, Inc., Key Employees  28
Genomic Health, Inc., Key Employee Biographies  29
Genomic Health, Inc., Other Locations  31
Genomic Health, Inc., Subsidiaries  31 


List of Figures
Genomic Health, Inc. Pipeline Products by Equipment Type  8
Genomic Health, Inc. Pipeline Products by Development Stage  12

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Europe industrial air filtration market size is projected to reach USD 1,690.8 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing implementation in various industries such as metal, cement and food & beverages among ot

Read More...

Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. Evolv

Read More...

Global automotive coatings market size is likely to be valued at USD 27.7 billion by 2022; as per a new research report by Radiant Insights, Inc. Vehicle aesthetics, UV radiation and temperature variation protection and enhance durability are certain

Read More...

Global amino acids market size is anticipated to be valued at USD 35.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in animal feed additive demand owing to regulate metabolism in livestock production owing to growi

Read More...

Global aquafeed market size is anticipated to be valued at USD 165.04 billion by 2022, as per a new research report by Radiant Insights, Inc. Increase in fish consumption for direct and indirect consumer applications is anticipated to drive the marke

Read More...
Choose License Type
Single User - US $750
Multi User - US $1500
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify